Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy (2018)
- Authors:
- USP affiliated authors: HOFF, PAULO MARCELO GEHM - FM ; MANO, MAX SENNA - FM
- Unidade: FM
- DOI: 10.1186/s40364-018-0135-x
- Subjects: QUIMIOTERAPIA ADJUVANTE; CÉLULAS ENDOTELIAIS; CO-TERAPIA; NEOPLASIAS MAMÁRIAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Biomarker research
- ISSN: 2050-7771
- Volume/Número/Paginação/Ano: v. 6, article ID 20, 6p, 2018
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
ARAI, Roberto J. et al. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. Biomarker research, v. 6, 2018Tradução . . Disponível em: https://doi.org/10.1186/s40364-018-0135-x. Acesso em: 26 jul. 2024. -
APA
Arai, R. J., Hoff, P. M., Mano, M. S., & Petry, V. (2018). Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. Biomarker research, 6. doi:10.1186/s40364-018-0135-x -
NLM
Arai RJ, Hoff PM, Mano MS, Petry V. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy [Internet]. Biomarker research. 2018 ; 6[citado 2024 jul. 26 ] Available from: https://doi.org/10.1186/s40364-018-0135-x -
Vancouver
Arai RJ, Hoff PM, Mano MS, Petry V. Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy [Internet]. Biomarker research. 2018 ; 6[citado 2024 jul. 26 ] Available from: https://doi.org/10.1186/s40364-018-0135-x - Malignancy-related hypercalcemia in the bishosphonate era
- Rare tumors research in emerging countries
- Ascite quilosa em paciente com carcinoma ductal invasivo de mama
- Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
- Câncer de mama HER2 positivo: tratamento (NEO) adjuvante - análise das pacientes tratadas no ICESP
- Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting
- Carcinoma neuroendócrino primário de mama (CNEM) - um diagnóstico raro: relato de dois casos
- Value of systemic staging in asymptomatic early breast cancer
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Informações sobre o DOI: 10.1186/s40364-018-0135-x (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
